title: Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
abstract: The IMiDs(®) immunomodulatory compounds lenalidomide and pomalidomide are agents with anti-inflammatory, immunomodulatory and anti-cancer activity. An excellent success rate has been shown for multiple myeloma in phase I/II clinical trials leading to Food and Drug Administration approval of lenalidomide. One mechanism by which these drugs could enhance anti-tumour immunity may be through enhanced dendritic cell (DC) function. Thalidomide, a compound structurally related to lenalidomide and pomalidomide, is known to enhance DC function, and we have investigated whether its analogues, pomalidomide and lenalidomide, also have functional effects on DCs. We used mouse bone marrow-derived DCs treated with 5 or 10 μm pomalidomide, or lenalidomide from day 1 of culture. Treatment with IMiD(®) immunomodulatory compounds increased expression of Class I (H2-Kb), CD86, and pomalidomide also increased Class II (I-Ab) expression in bone marrow-derived DCs, as measured by flow cytometry. Fluorescent bead uptake was increased by up to 45% when DCs were treated with 5 or 10 μm pomalidomide or lenalidomide compared with non-treated DCs. Antigen presentation assays using DCs primed with ovalbumin, and syngeneic T cells from transgenic OTI and OTII mice (containing MHC restricted, ovalbumin-specific, T cells) showed that both pomalidomide and lenalidomide effectively increased CD8(+) T-cell cross-priming (by up to 47%) and that pomalidomide alone was effective in increasing CD4(+) T-cell priming (by 30%). Our observations suggest that pomalidomide and lenalidomide enhance tumour antigen uptake by DCs with an increased efficacy of antigen presentation, indicating a possible use of these drugs in DC vaccine therapies.
authors: Centre for Infection and Immunity, Division of Clinical Sciences, St George's University of London, London, UK.
authors: Jake Y
authors: JY
authors: Henry
authors: Marie-Christine
authors: MC
authors: Labarthe
authors: Brendan
authors: B
authors: Meyer
authors: Prokar
authors: P
authors: Dasgupta
authors: Angus G
authors: AG
authors: Dalgleish
authors: Christine
authors: C
authors: Galustian
mesh_terms: D000818:Animals; D017951:Antigen Presentation / Q000187:drug effects / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002478:Cells, Cultured; D045142:Cross-Priming / Q000276:immunology*; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology; D005260:Female; D007155:Immunologic Factors / Q000276:immunology / Q000494:pharmacology; D000077269:Lenalidomide; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000276:immunology; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000276:immunology / Q000494:pharmacology
chemical_list: D000951:Antigens, Neoplasm; D007155:Immunologic Factors; D013792:Thalidomide; D010047:Ovalbumin; C467566:pomalidomide; D000077269:Lenalidomide
references: Br J Haematol. 2008 Jan;140(1):36-45
references: 17995965
references: J Exp Med. 2006 Nov 27;203(12):2691-702
references: 17101732
references: Blood. 2004 Mar 1;103(5):1787-90
references: 14512311
references: Stem Cells. 1996 Jul;14(4):376-87
references: 8843539
references: Cancer Immunol Immunother. 2009 Jul;58(7):1033-45
references: 19009291
references: J Exp Med. 1997 Jul 21;186(2):239-45
references: 9221753
references: Ann Pharmacother. 2008 Jan;42(1):91-8
references: 18094343
references: Curr Opin Immunol. 2003 Apr;15(2):138-47
references: 12633662
references: Clin Dev Immunol. 2010;2010:517493
references: 21076523
references: BMC Immunol. 2010 Mar 19;11:14
references: 20302610
references: Prostate. 2012 Jun 1;72(8):856-67
references: 21968939
references: Int J Med Microbiol. 2002 Feb;291(6-7):487-94
references: 11890548
references: J Immunol. 2007 Nov 1;179(9):5936-46
references: 17947667
references: J Immunol. 1998 Feb 1;160(3):1224-32
references: 9570538
references: J Drugs Dermatol. 2010 Nov;9(11):1383-92
references: 21061761
references: Nat Rev Drug Discov. 2010 Jul;9(7):513-4
references: 20592741
references: Nat Med. 1996 Oct;2(10):1096-103
references: 8837607
references: Cancer Immunol Immunother. 2004 Nov;53(11):963-77
references: 15146294
references: J Immunol. 2010 Aug 15;185(4):2140-6
references: 20644175
references: Expert Opin Biol Ther. 2010 Mar;10(3):369-79
references: 20132058
references: J Infect Dis. 2003 Mar 15;187(6):946-55
references: 12660941
references: Mol Biol Rep. 2010 Apr;37(4):1801-14
references: 19597962
references: Blood. 2010 Apr 1;115(13):2619-29
references: 19965642
references: Br J Cancer. 2009 Sep 1;101(5):803-12
references: 19638977
references: J Immunol. 2007 Apr 1;178(7):4017-21
references: 17371954
references: Int Immunol. 2000 Sep;12(9):1365-70
references: 10967032
references: Clin Cancer Res. 2008 Jul 15;14(14):4650-7
references: 18628480
references: Clin Cancer Res. 1995 Jan;1(1):95-103
references: 9815891
references: Cancer Res. 2009 Mar 15;69(6):2514-22
references: 19276342
references: J Clin Oncol. 2006 Dec 1;24(34):5343-9
references: 17088571